# Ruihua Venture Capital

> Ruihua Venture Capital is a VC fund in Shanghai backing Medical and Biotechnology. See 7 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Shanghai, China
- Total investments: 7
- Last investment: Dec 2023
- Lead investor: 14%
- Last updated: Aug 2026

Ruihua Venture Capital is a early stage venture capital firm.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 3 | 43% |
| Biotechnology | 3 | 43% |
| Health Care | 2 | 29% |
| Beauty | 1 | 14% |
| Dental | 1 | 14% |

12 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 2 | 29% |
| Series B | 2 | 29% |
| Series A | 1 | 14% |
| Funding Round | 1 | 14% |
| Venture - Series Unknown | 1 | 14% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Xijian Technology | Xijian Technology is committed to advancing the industrialization of innovative human biomechanics imaging technology. It focuses on health disciplines such as sports rehabilitation, dermatology and beauty, and disease diagnosis and treatment. |  | Seed | Dec 20, 2023 |  |
| Deyun Kangrui | Deyun Kangrui is a bio-medical high-tech enterprise that integrates R&D and the production of full-chain single-cell multi-omics technology. | $13.2M | Series A | Feb 06, 2023 |  |
| UniXell Biotechnology | Yuesai Biotechnology is a new-generation cell therapy drug developer, focusing on the development of a new generation of cell therapy drugs. | $31.4M | Seed | Mar 14, 2022 |  |
| Singlomics | Singlomics uses single-cell sequencing technology to develop antibody drugs for the treatment of infectious diseases and cancers. | $47.2M | Series B | Feb 02, 2022 |  |
| Tripod Preclinical Research Laboratories | Tripod is a Contract Research Organization in the biopharmaceutical space that provides preclinical research services for global pharma companies, R&D enterprises and institutes, and medical device developers. Tripod (TPR) is dedicated to nonclinical research (drug safety evaluation) for the candidates of new chemical entity (NCE), foodadditives, biologics，pesticides，veterinary drugs, and new cosmetics. | $156.3M | Venture - Series Unknown | Nov 05, 2021 |  |
| CytoLynx Therapeutics | CytoLynx Therapeutics is a R&D and commercial platform leveraging Cytovia’s unique technologies and product pipeline. | $45M |  | Sep 13, 2021 |  |
| Meiwei Dental Group | Meiwei Dental Medical Group is affiliated to Tianyi Group and is committed to opening up the overall health management of the whole people from the prevention, opening up to create the “China's first platform for oral medicine”, and through strategic investment, standard output, medical technology improvement and brand management as excellentin China. Oral medical brands and experts empower and achieve personalized development, and jointly promote the rapid development of the private dental health industry. Meiwei Dental cooperates with DNV GL, an internationally recognized certification body, to establish the first internationally-advanced dental clinic management system and medical standard “M+” management certification, and empowers partners through the construction of “five-one-one license”. Achieve scientific research and innovation and talent cultivation academicization, based on SaaS cloud platform informationization, medical and therapeutic environment comfort, medical service specialization, consumables and equipment refinement. Through the introduction of the "business partner" mechanism, the company has created a "stable and win-win" community of destiny, with the principle of complementarity and mutual integration, and the cooperation of partners in the medical capital, talent, technology, market, management and other dimensions. Carry out all-round empowerment. At present, Meiwei has invested in the acquisition of Weile Dental, Xinqiao Oral, Zhongshan Oral, DUANG DUANG Children's Oral, Meier Oral, Love Tooth, Hanmei Oral, Zhimei Dental, Tsinghua Sunshine Oral, Houcheng Oral, Hengmei Oral, Small The White Rabbit has a total of 12 dental chain brands covering 35 cities and 130 dental hospitals and clinics. | $154.3M | Series B | Jul 16, 2021 |  |

7 of 7 investments shown.

## Co-investors
- [GL Ventures](https://shizune.co/investors/profile/gl-ventures) — VC Fund, 2 deals together
- [GL Ventures LLC](https://shizune.co/investors/profile/gl-ventures-llc) — VC Fund, 2 deals together
- [Lapam Capital](https://shizune.co/investors/profile/lapam-capital) — VC Fund, 2 deals together
- [TF Capital](https://shizune.co/investors/profile/tf-capital) — VC Fund, 2 deals together
- [3H Health Investment](https://shizune.co/investors/profile/3h-health-investment) — VC Fund, 1 deal together
- [BioTrack Capital](https://shizune.co/investors/profile/biotrack-capital) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [Unilever Ventures](https://shizune.co/investors/profile/unilever-ventures) — VC Fund
- [Fab Co-Creation Studio Ventures](https://shizune.co/investors/profile/fab-co-creation-studio-ventures) — VC Fund
- [Flybridge](https://shizune.co/investors/profile/flybridge-capital) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [IDG Capital](https://shizune.co/investors/profile/idg-capital-partners) — VC Fund
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund
- [HSG](https://shizune.co/investors/profile/sequoia-capital-china) — VC Fund

## Featured in investor lists
- [Beauty Investors in China](https://shizune.co/investors/beauty-investors-china)
- [Beauty VC Funds in China](https://shizune.co/investors/beauty-vc-funds-china)

## FAQ

### What does Ruihua Venture Capital invest in?

Ruihua Venture Capital invests primarily in Medical, Biotechnology and Health Care startups, most often at Seed and Series B stage. Most of the 7 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Ruihua Venture Capital last invest?

The most recent investment recorded for Ruihua Venture Capital closed in Dec 2023. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co